Cannabis terpenes: A promising alternative for the relief of chemotherapy-induced neuropathic pain

A recent study published in Bread highlights a revolutionary discovery in the field of pain management. Researchers have discovered that terpenes in cannabis - the compounds responsible for the aroma and taste of cannabis - are a viable alternative to traditional methods of relieving pain. chemotherapy-induced neuropathic pain.

The study and its results

Directed by John Streicher, PhD, member of the Comprehensive Center for Pain & Addiction and Professor of Pharmacology at College of Medicine - Tucson, the study used a mouse model to explore the efficacy of terpenes in pain management caused by nerve damage induced by highly toxic chemotherapy drugs. The results were remarkable: individual terpenes not only matched, but sometimes exceeded, the pain relief provided by morphine. Moreover, the combination of terpenes with morphine resulted in a significant increase in analgesic effects.

«We looked at other aspects of terpenes, for example do they induce reward? Will it be addictive? Will it make you feel bad? What we found is that yes, terpenes do relieve pain, and they also have a pretty good side-effect profile,» Streicher noted in a University of Arizona release.

He added: «This raises the idea of a combination therapy - an opioid with a high level of terpenes - that could actually improve pain relief while blocking the addictive potential of opioids.»

Terpenes and pain management

The study, entitled «Cannabis sativa terpenes induce antinociception in a mouse model of chronic neuropathic pain via activation of adenosine A2A receptors», is pioneering in its examination of the side effects of terpenes in their role as potential analgesics. By activating adenosine A2A receptors, terpenes help to reduce the sensation of pain, which could revolutionize pain treatment, particularly for patients undergoing chemotherapy who suffer from neuropathic pain.

One of the main advantages of terpenes over traditional analgesics such as morphine is their side-effect profile. Unlike opioids, which are known for their addictive potential and serious side effects, terpenes offer a safer alternative. They do not induce the same level of reward or dependence, making them an attractive option for long-term pain management.

The most promising aspect of the study is the potential of combination therapies. By using terpenes in conjunction with opioids, it is possible to achieve better pain relief while reducing the risk of addiction. This approach could transform the way chronic pain is managed, bringing patients effective relief without the burden of unwanted side effects.